Matthew Ros

Insider Reports History

Entity: Individual
Location: C/O Epizyme, Inc., 400 Technology Square, Cambridge, MA
Signature: /s/ Evan D. Kearns, Attorney-in-Fact
All insider transactions: Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Stock	Role	Class	Num Shares	Value	Price $	Report Date	Ownership
Cogent Biosciences, Inc.	Director	Stock Option (Right to Buy)	44.7K	$321K	$7.19	Jun 5, 2024	Direct
Epizyme, Inc.	Executive Vice President, Chief Strategy & Business Officer	Common Stock, par value $0.0001	111K	$157K	$1.41	Aug 16, 2021	Direct
Epizyme, Inc.	Executive Vice President, Chief Strategy & Business Officer	Stock Option (Right to Buy)	134K	$75.1K	$0.56	Aug 16, 2021	Direct

Symbol	Company	Period	Transactions	Value $	Form Type	Date Filed	Role
COGT	Cogent Biosciences, Inc.	Jun 5, 2024	1	$0	4	Jun 13, 2024	Director
COGT	Cogent Biosciences, Inc.	Jan 2, 2024	1	$0	4	Jan 4, 2024	Director
COGT	Cogent Biosciences, Inc.	Oct 2, 2023	1	$0	4	Oct 3, 2023	Director
COGT	Cogent Biosciences, Inc.	Jul 3, 2023	1	$0	4	Jul 5, 2023	Director
COGT	Cogent Biosciences, Inc.	Jun 7, 2023	1	$0	4	Jun 8, 2023	Director
COGT	Cogent Biosciences, Inc.	Apr 3, 2023	1	$0	4	Apr 4, 2023	Director
COGT	Cogent Biosciences, Inc.	Jan 3, 2023	1	$12.9K	4	Jan 4, 2023	Director
COGT	Cogent Biosciences, Inc.	Oct 3, 2022	1	$12.9K	4	Oct 4, 2022	Director
COGT	Cogent Biosciences, Inc.	Jul 1, 2022	1	$12.9K	4	Jul 5, 2022	Director
COGT	Cogent Biosciences, Inc.	Jun 7, 2022	1	$0	4	Jun 9, 2022	Director
COGT	Cogent Biosciences, Inc.	Apr 1, 2022	1	$12.9K	4	Apr 5, 2022	Director
COGT	Cogent Biosciences, Inc.	Jan 3, 2022	1	$11.6K	4	Jan 4, 2022	Director
COGT	Cogent Biosciences, Inc.	Oct 1, 2021	1	$12.4K	4	Oct 5, 2021	Director
EPZM	Epizyme, Inc.	Aug 16, 2021	2	$0	4	Aug 18, 2021	Executive Vice President, Chief Strategy & Business Officer
COGT	Cogent Biosciences, Inc.	Jul 1, 2021	1	$10.6K	4	Jul 6, 2021	Director